Back to top
more

Profound Medical (PROF)

(Delayed Data from NSDQ)

$8.03 USD

8.03
10,214

0.00 (0.00%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $8.17 +0.14 (1.74%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer

Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -33.90% and 20.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

How Much Upside is Left in Profound Medical (PROF)? Wall Street Analysts Think 66.06%

The mean of analysts' price targets for Profound Medical (PROF) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of -12.90% and 21.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

What Makes Profound Medical (PROF) a New Buy Stock

Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?

Profound Medical (PROF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

After Plunging -15.27% in 4 Weeks, Here's Why the Trend Might Reverse for Profound Medical (PROF)

The heavy selling pressure might have exhausted for Profound Medical (PROF) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zoetis (ZTS) Matches Q4 Earnings Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Recent Price Trend in Profound Medical (PROF) is Your Friend, Here's Why

Profound Medical (PROF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 29.41% and 15.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Profound Medical (PROF) Q2 Earnings Expected to Decline

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Profound Medical (PROF) Reports Q1 Loss, Lags Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 11.11% and 9.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0% and 21.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for April 27th

FRPT, PING, and PROF have been added to the Zacks Rank #5 (Strong Sell) List on April 27, 2022

Profound Medical (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Misses Q4 Earnings and Revenue Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -37.67% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of -11.54% and -36.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Profound Medical (PROF) Report Negative Earnings Next Week? What You Should Know

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PROFOUND MEDICL (PROF) Reports Q2 Loss, Tops Revenue Estimates

PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -34.62% and 15.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?